The capabilities you require to grow an idea into a viable product and very different from the capabilities required to grow that product into a large scale business. Join us to discuss open innovation approaches to growing scalable businesses by leveraging the strengths of startups and corporates.
Fireside ChatPanel Discussion
About this event
The capabilities you require to grow an idea into a viable product and very different from the capabilities required to grow that product into a large scale business. Join us to discuss open innovation approaches to growing scalable businesses by leveraging the strengths of startups and corporates. We will also explore the equally important question of how startups can access corporate resources to achieve scale. Key questions that every entrepreneur or intrapreneur must answer:
- How do we validate that a novel idea is actually valuable before pouring time and money into it?
- If we prove that the idea is valuable, how do we pull together the talent we need to build the solution?
- Once we build it, how do we scale it fast, before a hundred competitors enter the market?
There are certain things that startups do well, like finding crazy brilliant solutions and identifying trends before they are visible to corporate strategy teams. And there are certain things that corporates do well, like pumping a new solution through giant market channels that have been build over decades to quickly gain market share. Nobody is good at everything so in this session we will explore how to grow future market-leading businesses by working together.
We will be joined by the head of BI X, Boehringer Ingelheim's innovation team, the head of open innovation at Siemens Healthineers, and an as-yet undisclosed startup to explore how they work with startups to build new businesses. Boehringer Ingelheim is one of the world's largest pharmaceutical companies, with revenues of €19 billion. The evolved from a baking soda manufacturer in 1885 into a leader in respiratory diseases, immunology, and diseases of the central nervous system. Siemens Healthineers is a leading medical technology company with revenues of €15 billion.